HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer Clinical Trials in Seoul

First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)